MedElevator
Войти в исследования Multiple sclerosis and related disorders · 2021
Natalizumab discontinuation in a Dutch real-world cohort.
Письмо в редакциюНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Coerver E M E, Wessels M H J, van Lierop Z Y G, van Kempen Z L E, Killestein J, Strijbis E M M
Аннотация
OBJECTIVE: To determine characteristics of multiple sclerosis patients that discontinued natalizumab treatment in a real-world cohort.
METHODS: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC.
RESULTS: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity.
CONCLUSIONS: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.
METHODS: Data was collected from an ongoing observational cohort study of all natalizumab treated patients at the Amsterdam UMC.
RESULTS: Of 253 patients who ever received natalizumab treatment, 147 have discontinued treatment. The most frequent reason for treatment discontinuation was JC-virus (JCV) positivity.
CONCLUSIONS: JCV positivity seems the most frequent reason for natalizumab discontinuation. The heterogeneity in treatment switches reflects the advances made in treatment options, and underlines the need for adequate patient counselling.